INBX.V Stock Overview
A clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Inhibrx, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$30.85 |
| 52 Week High | US$31.35 |
| 52 Week Low | US$30.78 |
| Beta | 2.88 |
| 11 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -1.28% |
Recent News & Updates
Recent updates
Shareholder Returns
| INBX.V | US Biotechs | US Market | |
|---|---|---|---|
| 7D | n/a | -0.4% | -1.2% |
| 1Y | n/a | 20.1% | 30.6% |
Return vs Industry: Insufficient data to determine how INBX.V performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how INBX.V performed against the US Market.
Price Volatility
| INBX.V volatility | |
|---|---|
| INBX.V Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 14.9% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: INBX.V has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine INBX.V's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 169 | Mark Lappe | inhibrx.com |
Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company’s therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications.
Inhibrx, Inc. Fundamentals Summary
| INBX.V fundamental statistics | |
|---|---|
| Market cap | US$1.79b |
| Earnings (TTM) | -US$271.15m |
| Revenue (TTM) | US$1.78m |
1,002x
P/S Ratio-6.6x
P/E RatioIs INBX.V overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| INBX.V income statement (TTM) | |
|---|---|
| Revenue | US$1.78m |
| Cost of Revenue | US$218.11m |
| Gross Profit | -US$216.32m |
| Other Expenses | US$54.83m |
| Earnings | -US$271.15m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -5.17 |
| Gross Margin | -12,132.47% |
| Net Profit Margin | -15,207.80% |
| Debt/Equity Ratio | 1,799.9% |
How did INBX.V perform over the long term?
See historical performance and comparison